NeuroSense Therapeutics Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.2M
- Price
- $3.82
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.14%
- Volume
- 12.9K
About
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Quick stats
Shares outstanding1.9M
Computed float1.2M
Float / shares65.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001875091
AI Summary
AI-generated1/24
standardbearishregulatory
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense received a Nasdaq Staff Determination on October 1, 2026 stating it failed to regain compliance with the $35 million minimum market value (MVLS) requirement, putting its shares and warrants at risk of delisting.
The company will request a Nasdaq Hearings Panel hearing, which stays any delisting pending a decision; the Panel may grant up to 180 additional days to regain compliance. Separately, NeuroSense regained compliance with the $1.00 minimum bid price rule after its 1-for-20 reverse split.
Management says it remains focused on advancing PrimeC in ALS, including the FDA-cleared Phase 3 PARAGON trial and a planned New Drug Submission to Health Canada, but there is no assurance the Panel will grant continued listing.
Red flags
- failed Nasdaq $35M MVLS requirement; delisting threatened pending Panel appeal
- recent 1-for-20 reverse split signals prior listing-compliance pressure
- no assurance Panel grants exception period; risk of trading suspension
- company notes financing risk — may not obtain financing on acceptable terms or at all